Form 4: Ionis Pharma EVP Granted Stock Options

Ionis Pharmaceuticals' EVP, Chief Clinical Development Officer Eugene Schneider was granted 19,350 non-qualified stock options with an exercise price of $79.67.

Summary

• Eugene Schneider, Executive Vice President and Chief Clinical Development Officer of Ionis Pharmaceuticals, Inc. (IONS), was granted 19,350 non-qualified stock options.
• The transaction date for this grant was January 2, 2026.
• The exercise price for these options is $79.67 per share.
• The options were granted under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.
• The options have an expiration date of January 1, 2036.
• Vesting schedule: 0 shares were exercisable on January 2, 2026. 25% of the shares will vest and become exercisable on January 2, 2027. The remaining shares will vest in 36 equal monthly installments over the subsequent three years.

Sentiment

Score: 6

Explanation: The filing reports a routine executive compensation event (stock option grant). While not directly impacting immediate financial performance, it is a positive for executive alignment and retention, hence a slightly positive sentiment.

Positives

• The grant of stock options aligns the executive's financial interests with those of the shareholders, incentivizing long-term performance.
• The options are part of an established equity incentive plan, indicating a structured approach to executive compensation.

Future Outlook

The vesting schedule for the granted stock options extends over several years, with 25% vesting on January 2, 2027, and the remainder vesting monthly over the subsequent three years, indicating a long-term incentive structure for the executive.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically an executive compensation event. It reflects standard practices in the biotechnology and pharmaceutical industry where equity-based compensation is a common tool to attract, retain, and incentivize key management personnel, aligning their interests with the company's long-term success.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of stock options to a key executive aligns management's long-term interests with shareholder value creation, potentially leading to improved performance.
• Employees: This type of compensation can serve as a benchmark or incentive for other employees, particularly those in leadership roles, within the company's broader compensation strategy.

Next Steps

• The stock options will follow a defined vesting schedule, with the first 25% vesting on January 2, 2027, and the remainder vesting monthly over the subsequent three years.

Key Dates

Keywords

Ionis Pharmaceuticals, IONS, Stock Options, Executive Compensation, Insider Transaction, Form 4, Equity Incentive Plan, Eugene Schneider